Noticias

Noticias

  • Título: J. Aaron Grantham, MD, Joins Corindus Vascular Robotics as Chief Medical Officer
  • Fecha: 03-08-2016

  • Dr. Grantham will lead initiatives to educate the interventional cardiology community on benefits of robotic therapy

    WALTHAM, MA - August 3, 2016 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that J. Aaron Grantham, MD, a leading interventional cardiologist, and an innovator in the treatment of chronic total occlusions (CTOs), has joined the company as Chief Medical Officer (CMO).

    Dr. Grantham will be spearheading Corindus' initiatives to educate the interventional cardiology community on the benefits of robotic therapy and will be leading efforts to develop clinical data to advance the CorPath® System’s applicability for additional clinical indications. As a practicing CMO, Dr. Grantham will continue treating patients at Saint Luke's Mid America Heart Institute.

    "I am excited to be joining Corindus during this time of growth for the company," said Dr. Grantham. "I believe that through a systematic, program-based approach, similar to my work in building CTO programs, robotic therapy will be able to reach its full potential. I look forward to working with other leaders in the field of interventional cardiology as we continue to optimize robotic therapy."

    Dr. Grantham is with Saint Luke’s Mid America Heart Institute, a member of Saint Luke’s Health System, as Associate Professor, University of Missouri-Kansas City School of Medicine. He also is Director of the school’s Cardiovascular Disease Fellowship Program and Director of Cardiovascular Medical Education at Saint Luke’s Hospital.

    "Dr. Grantham’s experience, knowledge and thought leadership will play an integral role in our continued growth and success,” said Mark Toland, President and Chief Executive Officer of Corindus “Together with an esteemed steering committee, Dr. Grantham will help Corindus achieve our vision and build a strong clinical roadmap for CorPath. We are excited to welcome him to the company in this critical position."



  • Fuente: endovascular.es